What actually works for fat loss?

A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascu...

A first-in-class dual GIP and GLP-1 receptor agonist with superior weight loss and glycemic control versus GLP-1 mono-ag...

An investigational once-weekly triple receptor agonist producing the largest pharmacological weight loss reported to dat...

The polyphenol behind the sirtuin era of longevity research and one of the most heavily trialled supplements in this dat...

A fibrinolytic enzyme from Bacillus subtilis natto fermentation with a genuinely large human trial record for a suppleme...

A mitochondrial-derived peptide with a real human literature: a common East Asian genetic variant, circulating levels me...

A mitochondrial-derived peptide with a genuine human observational record: it declines with age, runs high in children o...

An investigational once-daily oral GLP-1 receptor agonist that is a small molecule rather than a peptide, studied for ob...

An FDA-approved synthetic amylin analogue used with insulin to improve post-meal glucose control and reduce appetite.

Pfizer's oral small-molecule GLP-1 agonist whose development was discontinued after tolerability and safety signals.

A well-studied NAD+ precursor that reliably raises NAD+ in humans. Raising the molecule is proven; the mouse lifespan pr...

An investigational once-weekly amylin agonist studied with semaglutide (CagriSema) for powerful combined weight loss.

An investigational once-weekly GLP-1 and glucagon receptor dual agonist studied for obesity and metabolic liver disease.

An FDA-approved GLP-2 analogue that promotes intestinal growth in short bowel syndrome, reducing dependence on IV nutrit...

A fixed combination of the amylin analogue cagrilintide and semaglutide that produced about 23% weight loss in Phase 3 a...

Viking Therapeutics' dual GLP-1 and GIP agonist in Phase 3 as an injection, with an oral version showing rapid early wei...

Novo Nordisk's single-molecule GLP-1 and amylin agonist, in oral and injectable forms, that showed strong early weight l...

Altimmune's GLP-1 and glucagon dual agonist being developed for obesity and metabolic liver disease, with a focus on pre...

A long-acting GLP-1 agonist in Phase 3 development, notable for the potential of extended, less frequent dosing.

Lilly's selective amylin agonist that reached about 20% weight loss in Phase 2 with milder gut side effects than GLP-1 d...

An ultra-long-acting GLP-1 agonist with a roughly 15-day half-life built for once-monthly injection, the centerpiece of...

A once-weekly GLP-1/GIP dual agonist in the tirzepatide class that delivered 19.2% weight loss at 48 weeks in a Chinese...

Roche's signaling-biased GLP-1/GIP dual agonist that produced 22.5% placebo-adjusted weight loss at 48 weeks in Phase 2,...

Hengrui's once-daily oral GLP-1 pill with two positive Chinese Phase 3 trials (about 11% weight loss at 50 weeks), filed...

The selective androgen receptor modulator known on the gray market as ostarine, now in formal trials where 3 mg cut lean...

GSK's once-monthly FGF21 analog, acquired for $1.2 billion upfront, with FDA Breakthrough Therapy designation for MASH a...

A once-daily GLP-1 receptor agonist and the first GLP-1 approved specifically for obesity, with proven cardiovascular be...

The first approved GLP-1 receptor agonist, derived from Gila monster venom, which established the entire drug class.

A once-weekly GLP-1 receptor agonist for type 2 diabetes with demonstrated cardiovascular risk reduction.

An FDA-approved MC4R agonist for rare genetic forms of obesity driven by defects in the melanocortin pathway.

A direct NAD+ precursor studied for metabolic and physical-function benefits in aging, with early human trials and a con...

An investigational GLP-1 and glucagon receptor dual agonist studied for obesity and type 2 diabetes, with advanced trial...

The body's own hunger hormone and the natural trigger for growth hormone release, and the template for the entire GHRP p...

An FDA-approved once-daily GLP-1 receptor agonist for type 2 diabetes, also studied for effects beyond glucose control.

The natural gut hormone behind the entire GLP-1 drug class, released after eating to boost insulin and reduce appetite.

An investigational long-acting GLP-1 agonist that showed cardiovascular and kidney benefits in a large outcomes trial.

The hormone that raises blood sugar, FDA-approved as an emergency treatment for severe hypoglycemia and a target of the...

An investigational non-peptide weight-loss drug that suppresses appetite by acting on brain neurotransmitters.

A versatile antioxidant compound studied for diabetic nerve pain and metabolic health, sold as a supplement and used as...

An essential vitamin given by injection for deficiency and widely offered in wellness clinics for energy, though benefit...

Amgen's monthly-dosed obesity drug that pairs GLP-1 activation with GIP receptor blockade, reaching around 20% weight lo...

A once-weekly amylin analogue from Zealand and Roche being developed as a potentially better-tolerated obesity treatment...

A muscle-preserving antibody that blocks activin receptors to reduce fat while increasing lean mass, being studied along...

A triple GLP-1, GIP, and glucagon agonist developed mainly for metabolic liver disease.

Structure Therapeutics' once-daily oral small-molecule GLP-1 agonist that produced 16.3% placebo-adjusted weight loss at...

AstraZeneca's once-daily oral GLP-1 pill, 10.5% weight loss at 26 weeks in Phase 2b, now entering a broad Phase 3 progra...

Novo Nordisk's licensed triple agonist that produced up to 19.7% weight loss in 24 weeks in a Chinese Phase 2, the compa...

AstraZeneca's weekly amylin analog that jumped to Phase 3 in 2026 as a monotherapy and as an add-on to GLP-1 drugs, with...

An antibody that blocks the cannabinoid CB1 receptor outside the brain; alone it did little, but with semaglutide it rea...

Novo Nordisk's oral peripherally acting CB1 blocker: 7.1 kg weight loss in 16 weeks in Phase 2a, but with dose-related a...

Boehringer Ingelheim's first-in-class triple agonist that swaps glucagon for the NPY2 (PYY-type) satiety receptor, enter...

An antibody against latent myostatin, under FDA review for spinal muscular atrophy (decision due September 30, 2026) and...

Regeneron's anti-myostatin antibody, alone or with the anti-activin antibody garetosmab, preserved 51% to 81% of lean ma...

Biohaven's anti-myostatin/activin fusion protein being tested as a standalone weight-loss drug, with a Phase 2 obesity r...

A weekly FGF21 analog that missed its 36-week primary endpoint in compensated MASH cirrhosis but improved fibrosis in 29...

A glycoPEGylated FGF21 analog dosed weekly or every two weeks, now owned by Roche and in two Phase 3 MASH trials.

An oral pan-PPAR agonist for MASH whose 1,000-patient Phase 3 (NATiV3) completed its last patient visit in September 202...

A central metabolic coenzyme marketed via IV and injectable forms for anti-aging and recovery, with declining levels in...

A modified fragment of growth hormone developed for obesity that promotes fat metabolism in animals but failed to beat p...

An amino-acid-derived compound essential for fat metabolism, FDA-approved for genuine deficiency and widely used for ene...

A metabolite supplement studied for healthy aging. One mouse study reported longer life; the multi-site replication prog...

Pfizer's monthly amylin analog (from Metsera) with a 19-day half-life, being co-formulated with berobenatide into a once...

An oral AMPK activator with one 28-day human pilot in type 2 diabetes and recent mouse data, now sold as a research chem...

A PPAR-delta agonist GSK stopped developing, reportedly after long-term rodent studies produced cancers in multiple orga...

A Khavinson tetrapeptide sold as a pancreatic bioregulator riding the metabolic-health wave; the evidence is cell, anima...

An early GH secretagogue hexapeptide that strongly stimulates growth hormone and appetite.

The lipolytic C-terminal fragment of growth hormone studied in animals for fat loss without growth-hormone-like effects...

An experimental peptide that targets the blood supply of white fat, causing dramatic weight loss in primates but with si...

A natural gut hormone that promotes growth and repair of the intestinal lining, the basis for the drug teduglutide.

An experimental small-molecule enzyme inhibitor studied in animals for fat metabolism and muscle, popular on longevity r...

The natural melanocortin hormone behind skin pigmentation, appetite, and inflammation, and the template for melanotan an...

An experimental 'exercise mimetic' that activates energy-metabolism pathways in animals, with no human data yet.

Scholar Rock's follow-on to apitegromab, engineered for self-injection alongside GLP-1 drugs; Phase 1 readout expected i...

A 12 amino acid peptide discovered by AI-guided prohormone screening at Stanford that cut food intake by up to half in m...

An aminosterol PTP1B inhibitor from dogfish shark that regenerated heart tissue in zebrafish and mice and caused fat-spe...

A mitochondrial uncoupler that reversed obesity and insulin resistance in mice with a wider safety margin than DNP, now...

A natural NAD+ precursor found in coffee and fenugreek that improved muscle function in aged mice and worms and is lower...

A REV-ERB agonist marketed as an exercise mimetic. No human study of any design has been published, oral bioavailability...